Market research
FPRX Five Prime Therapeutics, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 37
- Dividend yield
- 0.0%
- Beta
- 4.63
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US33830X1046
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 37
- Dividend yield
- 0.0%
- Beta
- 4.63
About
About Five Prime Therapeutics, Inc
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors. Its preclinical programs include FPA157, an anti-CCR8 antibody that is engineered to eliminate CCR8-expressing CD4+ regulatory T cells within solid tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, and BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California. As of April 16, 2021, Five Prime Therapeutics, Inc. operates as a subsidiary of Amgen Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FPRX discussion.
5 years, 4 months ago
Five Prime Therapeutics, Inc is currently in a long term uptrend where the price is trading 100.5% above its 200 day moving average.
From a valuation standpoint, the stock is 92.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 105.7.
Five Prime Therapeutics, Inc's total revenue sank by 122.1% to $-708K since the same quarter in the previous year.
Its net income has increased by 33.5% to $-21M since the same quarter in the previous year.
Finally, its free cash flow grew by 55.5% to $-13M since the same quarter in the previous year.
Based on the above factors, Five Prime Therapeutics, Inc gets an overall score of 4/5.